Advertisement

Topics

Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits

12:40 EDT 14 Jun 2018 | Investing News Network

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS (ocrelizumab) data will be presented at the 4th Congress of the European Academy of Neurology (EAN) from June 16-19 in Lisbon, Portugal. As quoted in the press release: In a new exploratory analysis from the extended control period of the … Continued

The post Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits appeared first on Investing News Network.

Original Article: Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits

NEXT ARTICLE

More From BioPortfolio on "Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...